qa:qa_dcx-login
Fast, Simple, and Accurate PCR Testing for Primary Care.
Cepheid, a leader in molecular diagnostics, offers solutions that increase primary care efficiency while achieving better clinical care.
GeneXpert® Family of Systems Deliver Unmatched Results at the Point of Care
Point of care providers are at the frontline, working tirelessly in primary care, urgent care, and pediatric settings to deliver the highest standard of care to their patients, every day. Providers need accurate, onsite testing to properly diagnose and treat patients in one visit. Cepheid offers fast, accurate, and easy PCR results – the gold-standard solution for hospitals, laboratories, and near patient settings. Explore the GeneXpert® system and the GeneXpert® Xpress system, as well as our broad test menu, to take your team to the next level.
Designed for Point of Care
|
|
|
|
|
|
Testing as simple as 1, 2, 3
Respiratory Solutions
Build your Primary Care with a Single Solution for Respiratory Care
Test with the confidence of PCR using Cepheid’s GeneXpert system and Xpress® tests. Standardized CLIA waived molecular testing for any primary care setting — from health systems to standalone physician offices and specialty clinics. Achieve accurate, actionable results when and where they are needed the most.
Xpert® Xpress Strep A
Delivers accurate and timely results that optimizes fast treatment decisions
Xpert® Xpress CoV-2/Flu/RSV plus
Actionable rapid respiratory results to meet the challenges of co-circulating respiratory viruses
Xpert® Xpress Flu
A multi-target approach for the detection of influenza to mitigate potential impact of genetic shift and drift on strain detection
Xpert® Xpress SARS-CoV-2
Xpert® Xpress CoV-2 plus (US-IVD Moderately Complex)
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2
Xpert® Xpress CoV-2/Flu/RSV plus (US-IVD Moderately Complex)
Xpert® Xpress Strep A
Delivers accurate and timely results that optimizes fast treatment decisions
Xpert® Xpress CoV-2 plus
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2
Women’s and Sexual Health Solutions
Build Your Primary Care with a Single Solution for Women's and Sexual Health
Primary Care is at the forefront of the fight, certain studies have found that primary care clinics might diagnose up to half of the reported STDs.^+ Achieve accurate, actionable results when and where they are needed the most.
Xpert® TV
Fast and Accurate Diagnosis of Trichomoniasis in 90 minutes or less
Xpert® CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
Xpert® GBS TEST
Xpert® Xpress MVP
Multiplex vaginal panel that enables results within 60 minutes from a single specimen for Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis
Select your area of interest
References
US-IVD. In Vitro Diagnostic Medical Device
* These tests have not been FDA cleared or approved. These tests have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2 plus has been authorized only for the detection of nucleic acids from SARS-CoV-2, and not for any other viruses or pathogens. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
^ Full test runtime is 36 minutes. SARS-CoV-2 positive results available in as soon as 25 minutes with early assay termination.
+Brackbill RM, Sternberg MR, Fishbein M. Where do people go for treatment of sexually transmitted diseases? Fam Plann Perspect 1999;31:10–5. Cross Refexternal icon Pub Medexternal icon